Patents by Inventor Anilkumar G. Nair

Anilkumar G. Nair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10519115
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 31, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Purakkattle Biju, Steven L. Colletti, Qun Dang, Pawan Dhondi, Candido Gude, Hubert Josien, Nam Fung Kar, Anilkumar G. Nair, Ravi P. Nargund, De-Yi Yang, Cheng Zhu
  • Publication number: 20190389909
    Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole HA, Jian Liu, Sobhana Babu Boga
  • Patent number: 10000454
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: June 19, 2018
    Assignee: Merck Sharp & Dohme
    Inventors: Tesfaye Biftu, Purakkattle Biju, Timothy A. Blizzard, Zhengxia Chen, Matthew J. Clements, Mingxiang Cui, Jessica L. Frie, William K. Hagmann, Bin Hu, Hubert Josien, Anilkumar G. Nair, Christopher W. Plummer, Cheng Zhu
  • Publication number: 20170081287
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 23, 2017
    Inventors: Tesfaye Biftu, Purakkattle Biju, Timothy A. Blizzard, Zhengxia Chen, Matthew J. Clements, Mingxiang Cui, Jessica L. Frie, William K. Hagmann, Bin Hu, Hubert Josien, Anilkumar G. Nair, Christopher W. Plummer, Cheng Zhu
  • Publication number: 20160257652
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: November 10, 2014
    Publication date: September 8, 2016
    Inventors: Tesfaye Biftu, Purakkattle Biju, Steven L. Colletti, Qun Dang, Pawan Dhondi, Candido Gude, Hubert Josien, Nam Fung Kar, Anilkumar G. Nair, Ravi P. Nargund, De-Yi Yang, Cheng Zhu
  • Publication number: 20140005165
    Abstract: Disclosed are CCR2 antagonists of Formula (I) or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.
    Type: Application
    Filed: March 14, 2012
    Publication date: January 2, 2014
    Inventors: Anilkumar G. Nair, Jose S. Duca, Michael P. Dwyer, Joseph A. Kozlowski, Stuart B. Rosenblum
  • Publication number: 20140005174
    Abstract: Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.
    Type: Application
    Filed: March 14, 2012
    Publication date: January 2, 2014
    Inventors: Anilkumar G. Nair, Joseph A. Kozlowski, Jose S. Duca, Stuart B. Rosenblum
  • Publication number: 20130345254
    Abstract: Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salts thereof, wherein A, B, R, and R6 are as defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.
    Type: Application
    Filed: March 14, 2012
    Publication date: December 26, 2013
    Inventors: Anilkumar G. Nair, Joseph A. Kozlowski